Group 1 - The 2025 Analyst Conference and the 7th Sina Finance "Golden Unicorn" Best Analyst Awards Ceremony were held in Shanghai, gathering over 300 industry experts to discuss future opportunities in the Chinese capital market [1] - The top honor for the 7th Sina Finance Golden Unicorn Elite Analyst in the innovative drug sector was awarded to the Zheshang Securities research team, led by Chief Analyst Wu Tianhao [1] Group 2 - The strategy for the high-value consumables sector in 2026 indicates optimism due to policy optimization, with expectations for revenue recovery and new product launches [2] - The medical device sector is expected to see performance recovery driven by the resumption of in-hospital bidding and the "Belt and Road" initiative, despite a decline in profit in the first three quarters of 2025 [2] - The home medical sector is anticipated to regain growth, supported by overseas expansion and recovery in revenue and profit growth in 2025 [2] Group 3 - Investment recommendations include high-value consumables companies with cleared procurement risks and new product launches, such as Microelectrophysiology, Aikang Medical, and Weikang Medical [3] - Medical device and home medical companies expected to see steady revenue growth include Mindray Medical, Meihua Medical, and Yuyue Medical, among others [3]

北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第五次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国·北京 EUME 3 PT VIJAN LAW OFFICES 北京 BEIJING ·上海 SHANGHAI ·深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 致:深圳华大智造科技股份有限公司 北京市嘉源律师事务所 关于深圳华大智造科技股份有限公司 2025 年第五次临时股东大会的 法律意见书 嘉源(2025)-04-867 北京市嘉源律师事务所(以下简称"本所")接受深圳华大智造科技股份有 限公司(以下简称"公司")的委托,根据《中华人民共和国公司法》(以下简 称"《公司法》")《上市公司股东会规则》(以下简称"《股东会规则》") 等现行有效的法律、行政法规、部门规章、规范性文件(以下简称"法律法规") 以及《深圳华大智造科技股份有限公司章程》(以下简称"《公司章程》")的 有关规定,指派本所律师对公司2025年第五次临时股东大会(以下简称"本次股 东大会"）进行见证,并依法出具本法律意见书。 为 ...

深圳华大智造科技股份有限公司 证券代码：688114 证券简称：华大智造 公告编号：2025-074 2025年第五次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 26 日 （二） 股东大会召开的地点：深圳市盐田区梅沙街道云华路 9 号华大时空中心 C 区国际会议中心 419 会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 127 | | --- | --- | | 普通股股东人数 | 127 | | 2、出席会议的股东所持有的表决权数量 | 222,169,043 | | 普通股股东所持有表决权数量 | 222,169,043 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 53.8554 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量 ...

Core Insights - The precision medicine sector experienced a 1.92% increase on November 24, with Guomai Technology leading the gains [1] - The Shanghai Composite Index closed at 3836.77, up 0.05%, while the Shenzhen Component Index closed at 12585.08, up 0.37% [1] Stock Performance - Guomai Technology (002093) closed at 12.19, up 10.02% with a trading volume of 446,600 shares and a transaction value of 536 million [1] - Zhongyuan Xiehe (600645) also rose by 10.02% to 28.23, with a trading volume of 169,100 shares and a transaction value of 468 million [1] - Other notable performers include: - Toukeng Life (300642) at 19.51, up 3.34% [1] - Beirui Gene (000710) at 11.97, up 3.28% [1] - Yangjin Medical (300030) at 7.90, up 3.27% [1] Capital Flow - The precision medicine sector saw a net inflow of 526 million from institutional investors, while retail investors experienced a net outflow of 143 million [2] - The main capital inflow and outflow for key stocks include: - WuXi AppTec (603259) with a net inflow of 251 million [3] - Guomai Technology (002093) with a net inflow of 241 million [3] - Zhongyuan Xiehe (600645) with a net inflow of 102 million [3]

11 月 21 日，以 " 智领健康未来 " 为主题的 2025 华夏大健康产业发展暨康复服务大会在北京召开。作为连续四届引领行业风向的标杆盛会，科技与创新 始终是贯穿全程的灵魂主线，而医疗健康企业在环境、社会及治理方面的表现同样被社会各界关注。 万得 ESG高级分析师 受邀发表了主题演讲，详细介绍了蒲公英指数的构建背景、评估体系及市场表现，强调该指数为医疗健康行业可持续发展提供了重 要参考。 万得首先介绍了 Wind 万得的业务背景： "Wind 是一家专业化的信息服务机构，为金融领域开发了信息检索、数据提取及组合管理等专业工具，是国内外 机构投资者的重要合作伙伴。 " 她特别指出， Wind 构建的独立 ESG 评级体系已广泛应用于政策研究、金融决策和企业实践当中，例如国务院发展研究 中心发布的报告及可持续挂钩债券发行实践。 蒲公英指数亦是 Wind ESG 评级体系的一次创新性应用。该指数由华夏时报大健康研究院与万得联合研发，从医疗健康领域 A 股 495 家公司中精选前 50 家组成 " 蒲公英 50 指数 " ，港股 262 家公司中精选 30 家组成 " 蒲公英 30 指数 " ，每月根据 ESG ...

Market Overview - The precision medicine sector experienced a decline of 1.61% on November 21, with Berry Genomics leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Key stocks in the precision medicine sector showed varied performance, with the following notable changes: - United Imaging Healthcare (688271) increased by 2.15% to a closing price of 133.50 [1] - Berry Genomics (000710) fell by 8.67% to a closing price of 11.59, with a trading volume of 233,200 shares and a turnover of 278 million [2] - WuXi AppTec (603259) decreased by 2.00% to a closing price of 91.80, with a significant trading volume of 346,800 shares and a turnover of 3.197 billion [1] Capital Flow - The precision medicine sector saw a net outflow of 678 million from institutional investors, while retail investors contributed a net inflow of 705 million [2] - The following stocks experienced notable capital flows: - New Open Source (300109) had a net inflow of 22.76 million from institutional investors [3] - ST Xiangxue (300147) faced a significant net outflow of 17.12 million from institutional investors [3]

| 年第五次临时股东大会会议须知 3 2025 | | --- | | 2025 年第五次临时股东大会会议议程 5 | | 年第五次临时股东大会会议议案 7 2025 | | 《关于修订〈公司章程〉并办理工商变更登记的议案》 7 | | 《关于修订、制定公司部分治理制度的议案》 8 | | 《关于增加公司 2025 年度日常关联交易预计额度的议案》 10 | | 《关于使用部分超募资金永久补充流动资金的议案》 12 | 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议资料 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会 会议资料 2025 年 11 月 1 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议资料 深圳华大智造科技股份有限公司 2025 年第五次临时股东大会会议须知 为保障深圳华大智造科技股份有限公司（以下简称"公司"）全体股东的合 法权益，维护股东大会的正常秩序，保证股东大会的议事效率，确保本次股东大 会如期、顺利召开，根据《中华人民共和国公司法》（以下简称《公司法》）、 《深圳华大智造科技股份有限公司章程》（以下简称《公司章程》）、《深圳华 大智造 ...

Core Points - Shenzhen BGI Genomics Co., Ltd. announced a change in its continuous supervision sponsor representative [1] - CITIC Securities, the sponsor for the company's 2022 A-share IPO project, has replaced the original representative due to work adjustments [1] - The new sponsor representatives are Lu Ming and Wang Helin, ensuring the continuity of supervision duties [1] Summary by Sections - **Company Announcement** - The company confirms the authenticity and completeness of the announcement [2] - The board expresses gratitude to the outgoing representative for his contributions [1] - **Change of Sponsor Representative** - The original sponsor representative, Xiao Shaochun, is replaced by Wang Helin to maintain orderly supervision [1] - The continuous supervision period is set to last until December 31, 2025 [1]

Core Viewpoint - BGI Genomics announced a change in its sponsor representative for the ongoing supervision of its 2022 A-share IPO project, ensuring continuity in oversight responsibilities [1] Group 1 - CITIC Securities was appointed as the sponsor for BGI Genomics' 2022 A-share IPO project, with the supervision period lasting until December 31, 2025 [1] - The original sponsor representatives, Mr. Xiao Shaochun and Mr. Lu Ming, were responsible for the continuous supervision duties [1] - Mr. Xiao Shaochun will no longer be responsible for the supervision due to a work adjustment, and Mr. Wang Helin has been appointed to take over his responsibilities [1]

深圳华大智造科技股份有限公司 关于变更持续督导保荐代表人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 深圳华大智造科技股份有限公司（以下简称"公司"）于近日收到中信证券 股份有限公司（以下简称"中信证券"）出具的《关于更换保荐代表人的函》。 中信证券作为公司 2022 年 A 股首次公开发行项目的保荐机构，原委派肖少春先 生和路明先生为保荐代表人履行持续督导职责，持续督导期至 2025 年 12 月 31 日止。 证券代码：688114 证券简称：华大智造 公告编号：2025-073 原保荐代表人肖少春先生现因工作调整，不再负责对公司的持续督导工作， 为保证持续督导工作的有序进行，中信证券现委派王贺麟先生（简历详见附件） 接替肖少春先生担任公司的保荐代表人，并继续履行持续督导的相关职责和义务。 本次变更后，公司 2022 年 A 股首次公开发行项目的保荐代表人为路明先生 和王贺麟先生。本次变更不影响中信证券对公司的持续督导工作，公司董事会对 肖少春先生在担任公司保荐代表人期间做出的贡献表示衷心感谢！ 特此公告。 王贺 ...